{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380011146477089296.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"D. Card"}],"foaf:familyName":[{"@value":"Card"}],"foaf:givenName":[{"@value":"D."}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360011146477089280","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1093/annonc/mdy517"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0923753419310750?httpAccept=text/xml"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0923753419310750?httpAccept=text/plain"},{"@type":"URI","@value":"http://academic.oup.com/annonc/article-pdf/30/3/397/28255129/mdy517.pdf"},{"@type":"HANDLE","@value":"2072/444702"}],"notation":[{"@value":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1093/annonc/mdy517_Wgb5pbLXwys22XDs7Oxk3ak6FJa"}]}